Factors Associated With Use of Telemedicine for Follow-Up of SLE in the COVID-19 Outbreak

Ho So†, Evelyn Chow, Isaac T. Cheng†, Sze-Lok Lau, Tena K. Li, Cheuk-Chun Szeto† and Lai-Shan Tam*†

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China

Objective: To investigate the factors associated with telemedicine (TM) use for follow-up of Systemic Lupus Erythematosus (SLE) patients in the COVID-19 pandemic.

Methods: This was a single-centered cross-sectional study conducted in Hong Kong. Consecutive patients followed up at the lupus nephritis clinic were contacted for their preference in changing the coming consultation to TM in the form of videoconferencing. The demographic, socioeconomic, and disease data of the first 140 patients opted for TM and 140 control patients preferred to continue standard in-person follow-up were compared.

Results: The mean age of all the participants was 45.6 ± 11.8 years, and the disease duration was 15.0 ± 9.2 years. The majority of them were on prednisolone (90.0%) and immunosuppressants (67.1%). The mean SLEDAI-2k was 3.4 ± 2.4, physician global assessment (PGA) was 0.46 ± 0.62 and Systemic Lupus International Collaborating Clinics (SLICC) damage index was 0.97 ± 1.23. A significant proportion of the patients (72.1%) had 1 or more comorbidities. It was found that patients with higher mean PGA (TM: 0.54 ± 0.63 vs. control: 0.38 ± 0.59, p = 0.025) and family monthly income > USD 3,800 (TM: 36.4% vs. control: 23.6%; p = 0.028) preferred TM, while full-time employees (TM: 40.0% vs. control: 50.7%; p = 0.041) preferred in-person follow-up. These predictors remained significant in the multivariate analysis after adjusting for age and gender. No other clinical factors were found to be associated with the preference of TM follow-up.

Conclusion: When choosing the mode of care delivery between TM and physical clinic visit for patients with SLE, the physician-assessed disease activity and patient’s socio-economic status appeared to be important.

Keywords: COVID-19, lupus nephritis, systemic lupus erythematosus, telehealth, telemedicine

INTRODUCTION

Since coronavirus disease 2019 (COVID-19) was declared a pandemic, the rapidly increasing number of cases and deaths overwhelmed the health care system worldwide. Systemic lupus erythematosus (SLE) is a chronic remitting-relapsing disease that affects multiple organ systems. Patients with SLE are at heightened risk of infection due to the underlying disease and the use of immunosuppressive therapies (1). The increased prevalence of comorbidities, such as hypertension and cardiovascular diseases, have been reported to be poor prognostic factors of COVID-19 (2, 3).
During this extraordinary time, lupus patients face the difficult choice between risking COVID-19 exposure during a clinician visit and postponing needed care. Patients with SLE typically require regular follow-up (FU) visits to ensure early detection of flares and to monitor the toxicity of immunosuppressive therapy. The unattended patients are at risk of sub-optimal disease control which will lead to damage accrual and high costs (4, 5). An alternative option would be to adopt telemedicine (TM) or telehealth, the use of telecommunication technologies to provide medical information and services. In fact, the use of TM to reduce potential exposure to COVID-19 has been recommended by international rheumatology societies (6, 7). Communication via telephone or video consultations are recommended over emails because of privacy concerns (8). Specific statements on the scope and limitations of the use of video consultations in rheumatology patients have also been published (9).

Despite being widely used during the pandemic, evidence of TM in rheumatology is sparse. According to a systematic review in 2017, there is no good evidence in supporting the use of TM for the management of rheumatic diseases (10). In total, 2 studies during the COVID-19 outbreak reported moderate acceptance of TM as the mode of care in patients with rheumatic diseases (11, 12). However, there is no data on the clinical factors associated with the use of TM in patients with SLE. We hypothesized that the decision of choosing TM as the mode of FU could be predicted by certain patient profile.

In this study, we aimed to examine the demographic, socio-economic, psychological, disease, and treatment factors associated with the patient’s preference of use of TM for FU of SLE.

METHODS
Study Design and Patients
This was a single-center, observational, cross-sectional study. The study was performed at the lupus nephritis clinic of a regional hospital in Hong Kong where most of the patients reside nearby. From May 1 to November 30, 2020, all consecutive adult patients with SLE, according to the 2019 EULAR/ACR classification criteria, were invited to participate in the study (13). Patients (or their carers) needed to possess the technology required to conduct a TM visit (a smartphone, tablet or computer with audio and video capabilities and internet connection) via a real-time video conferencing software ZOOM (Zoom Video Communications Inc, California, US). Patients on intravenous cyclophosphamide were excluded. All patients who had given written informed consent were asked for their interest in changing the coming scheduled FU to TM-based in the form of a videoconference. The first 140 patients agreed to use TM care were recruited. Another 140 consecutive patients who preferred to continue standard FU were enrolled as controls. All participants were asked to complete a set of questionnaires including the LupusQol, Health Assessment Questionnaire Disability Index (HAQ-DI), and Hospital Anxiety and Depression Scale (HADS). The LupusQol (0–100, 100 worst) is a disease-targeted patient reported outcome measure that was developed and validated for SLE patients (14). It consists of both 8 health-related and 4 non–health related domains to enable an understanding of the broader burden of the disease. HAQ-DI (0–3, 3 most disabled) covers various common daily activities to assess disability (15). HADS (>8 denotes anxiety or depression) was used to assess anxiety and depression in medical patients (16). The socio-economic status of the patients was also collected through questionnaire which has been used in studies of local patients with autoimmune rheumatic diseases (17, 18). The study was approved by the local research ethics committee (The Joint Chinese University of Hong Kong – New Territories East Cluster Clinical Research Ethics Committee, No. 2020-0254) and conducted according to the principles of the Declaration of Helsinki.

Assessments
The disease variables recorded included disease duration, comorbidities, nephritis class, ever presence of rash/joint pain, proteinuria, medications, disease activity, and Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI) (19). SLE disease activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2k) and physician global assessment [PGA (0–3, 3 most active)] (19). Disease remission was defined as absence of clinical activity with no use of systemic glucocorticoids (GC) and immunosuppressive agents; and lupus low disease activity state (LLDAS) as a SLEDAI 2k ≤ 4, PGA ≤ 1 with GC ≤ 7.5 mg of prednisone daily and well tolerated standard maintenance doses of immunosuppressive agents (20). All investigations and assessments were performed within 1 month before or after the patients were recruited. The clinical assessments of the control group were done face-to-face while those for the TM group were by either face-to-face or videoconferencing. All patients were required to come to the hospital for blood and urine tests prior to the scheduled FU. The clinical data were retrieved from the electronic health record (EHR) manually and were documented into a computer database for analysis.

Statistical Analysis
The overall demographic and clinical characteristics of the recruited patients were reported as mean values with standard deviations for continuous variables and as numbers and percentages for categorical variables. The patients in the TM and control groups were compared by chi-square test or fisher’s exact test and student t-test where appropriate. Binary logistic regression was conducted for analysis of independent predictors with respect to preference over TM FU. Age, gender, and other predictors with p < 0.1 in the univariate analyses were put into the regression model. A 2-tailed probability value of p < 0.05 was considered statistically significant. Statistical analyses were performed using the Statistics Package for Social Sciences V.26.0 (IBM Corporation, Armonk, NY, USA).

RESULTS
A total of 332 patients with SLE were screened and 34 were excluded due to the lack of required equipment. The
TABLE 1 | Disease data of the recruited patients and comparison between the telemedicine/standard follow-up groups.

|                          | Overall (n = 280) | Telemedicine group (n = 140) | Standard follow-up group (n = 140) | P-value |
|--------------------------|-------------------|-----------------------------|-----------------------------------|---------|
| Age in years             | 45.6 ± 11.8       | 44.6 ± 11.4                 | 46.6 ± 12.1                       | 0.159   |
| Gender: Female           | 256 (91.4)        | 127 (90.7)                  | 129 (92.1)                        | 0.669   |
| Ever presence of:        |                   |                             |                                   |         |
| Rash                     | 170 (60.8)        | 87 (62.1)                   | 82 (58.6)                         | 0.527   |
| Joint pain               | 174 (62.1)        | 92 (65.7)                   | 82 (58.6)                         | 0.247   |
| Disease duration in years| 15.8 ± 9.5        | 15.0 ± 9.3                  | 16.5 ± 9.6                        | 0.176   |
| Nephritis class III, IV or V | 247 (88.2)    | 122 (87.1)                  | 125 (89.3)                        | 0.662   |
| 24 hour urine proteinuria in gram | 0.45 ± 0.60 | 0.50 ± 0.63                 | 0.40 ± 0.57                       | 0.176   |
| Current use of prednisolone | 252 (90.0)     | 125 (85.7)                  | 127 (90.7)                        | 0.690   |
| Daily prednisolone dose in mg | 5.8 ± 6.1      | 5.3 ± 4.5                   | 6.4 ± 7.4                         | 0.143   |
| Use of immunosuppressant:|                   |                             |                                   |         |
| Mycophenolate mofetil    | 105 (37.5)        | 62 (44.3)                   | 43 (30.7)                         | 0.611   |
| Calcineurin inhibitors   | 49 (17.5)         | 20 (14.3)                   | 29 (20.7)                         |         |
| Azathioprine             | 28 (10)           | 12 (8.6)                    | 16 (11.4)                         |         |
| Methotrexate             | 3 (1.1)           | 1 (0.7)                     | 2 (1.4)                           |         |
| Rituximab                | 3 (1.1)           | 1 (0.7)                     | 2 (1.4)                           |         |
| SLEDAI-2K                | 3.4 ± 2.4         | 3.5 ± 2.3                   | 3.3 ± 2.4                         | 0.366   |
| PGA                      | 0.48 ± 0.62       | 0.54 ± 0.63                 | 0.38 ± 0.59                       | 0.025   |
| LLDAS                    | 196 (70)          | 92 (65.7)                   | 104 (74.3)                        | 0.160   |
| Remission                | 5 (1.8)           | 0 (0)                       | 5 (3.6)                           | 0.060   |
| Presence of comorbidity  | 202 (72.1)        | 100 (71.4)                  | 102 (72.9)                        | 0.790   |
| Number of comorbidity    | 1.5 ± 1.4         | 1.4 ± 1.4                   | 1.6 ± 1.4                         | 0.301   |
| SDI                      | 0.97 ± 1.23       | 0.95 ± 1.21                 | 1.00 ± 1.26                       | 0.732   |
| HAQ-DI                   | 0.20 ± 0.40       | 0.23 ± 0.45                 | 0.18 ± 0.34                       | 0.300   |
| HADS:                    |                   |                             |                                   |         |
| Anxiety scale            | 5.9 ± 4.0         | 5.9 ± 4.1                   | 6.0 ± 3.9                         | 0.776   |
| Depression scale         | 5.6 ± 3.9         | 5.6 ± 4.3                   | 5.6 ± 3.5                         | 0.954   |
| LupusQoL score for:      |                   |                             |                                   |         |
| Physical health          | 80.5 ± 18.8       | 79.6 ± 20.2                 | 81.5 ± 17.1                       | 0.406   |
| Pain                     | 81.3 ± 18.8       | 82.1 ± 19.2                 | 80.4 ± 18.4                       | 0.456   |
| Planning                 | 83.8 ± 18.7       | 83.8 ± 18.7                 | 83.8 ± 18.8                       | 0.996   |
| Intimate relationship    | 77.1 ± 24.9       | 74.7 ± 27.6                 | 79.7 ± 21.3                       | 0.201   |
| Burden to others         | 73.9 ± 23.2       | 75.4 ± 22.3                 | 72.4 ± 24.1                       | 0.295   |
| Emotional health         | 81.2 ± 17.4       | 82.1 ± 17.5                 | 80.2 ± 17.3                       | 0.383   |
| Body image               | 78.8 ± 22.1       | 78.4 ± 23.2                 | 79.1 ± 21.0                       | 0.793   |
| Fatigue                  | 74.2 ± 20.6       | 75.6 ± 19.9                 | 72.7 ± 21.3                       | 0.247   |

Data are reported as mean ± SD or number (%). SLEDAI-2k: Systemic Lupus Erythematosus Disease Activity Index 2000; PGA: physician global assessment; LLDDAS: lupus low disease activity state; SLEDAI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index; HAQ-DI, Health Assessment Questionnaire Disability Index; and HADS, Hospital Anxiety and Depression Scale.

Demographic and disease characteristics of the first 140 patients preferred TM and 140 controls are presented in Table 1. The mean age of the 280 recruited patients was 45.6 ± 11.8 years. There was a female predominance (91.4%). The mean disease duration was 15.0 ± 9.2 years. The majority (88.2%) had biopsy proven lupus nephritis class III, IV, or V. The mean SLEDAI-2k was 3.4 ± 2.4, mean PGA was 0.46 ± 0.62 and SDI was 0.97 ± 1.23. Almost all of them (90%) were on prednisolone with a mean daily dose of 5.8 ± 6.1 mg. In total, 2 third of the patients (67.1%) were on immunosuppressive agents with the most common being mycophenolate mofetil followed by calcineurin inhibitors. While 70% of the patients were in LLDDAS, only 5 (1.8%) had disease remission. A significant proportion of the patients (72.1%) had 1 or more comorbidities. The mean HAQ-DI was 0.20 ± 0.40. Regarding the anxiety and depression scales, 32.9% and 29.6% of the patients had score equal to or greater than 8, respectively. The socio-economic profile of the patients is presented in Table 2.

Univariate analyses showed that higher PGA (TM: mean 0.54 ± 0.63 vs. control: 0.38 ± 0.59; p = 0.025) and family monthly income > USD3, 800 (HKD30, 000) (TM: 51/140, 36.4% vs. control: 33/140, 23.6%; p = 0.028) were associated with the preference of TM use, while fulltime employment (TM: 56/140, 40.0% vs. control: 71/140, 50.7%; p = 0.041) was related to physical FU. There was no statistically significant difference in the objective parameters of disease activity. There was also no other difference in the demographics, socio-psychological factors, lupus manifestations, disease damage, co-morbidities, and pharmacotherapies between the 2 groups of patients.
Binary logistic regression analysis revealed higher PGA, family monthly income > USD3,800, and non-fulltime employment status remained independently associated with TM care (OR 1.05 95% CI 1.01–1.09 \( p = 0.027 \), OR 1.90 95% CI 1.24–3.79 \( p = 0.007 \), OR 1.89 95% CI 1.13–3.17 \( p = 0.015 \), respectively) after adjustment for age and gender.

**DISCUSSION**

As we define the new normal for ambulatory care in the COVID era, we need a new approach to provide FU for our SLE patients, and TM is an obvious option. While there was conflicting evidence about the effectiveness of TM in an early systematic review, subsequent individual studies on specific disease entities have been promising (21). When compared with in-person care, TM resulted in greater reductions of severity in patients with depression, equally reliable outcome assessment in patients with low back pain, and similarly improved skin score in patients with psoriasis (22–24). It was also suggested that TM helped to balance the healthcare workforce and to address manpower insufficiency (25, 26). A randomized controlled trial in 2018 found that a TM FU could achieve similar disease control as conventional care in rheumatoid arthritis patients with low disease activity or remission (27). The COVID-19 pandemic compelled the rapid adoption of TM in rheumatology. For instance, 1 Italian study reported a smooth switch of 80% of the outpatient appointments to TM (28). Another study done in the US noted that TM peaked at 92% of the total visits and was accompanied by a large shift in provider EHR utilization (29). A research letter reported that 52.7% of patients with predominantly arthritis in a rheumatology department in Spain considered phone consultation to be useful, and no specific patient profile was associated with this opinion (30). It was also commented by the authors of a study reporting the experience of a rheumatology teleclinic in the UK that old age or presence of comorbidities were not reasons for not offering TM FU (31). However, data relate specifically to patients with SLE are scarce.

It might appear intuitive that TM is more suitable and easily accepted by patients with milder disease. On the other hand, the benefit of offering TM FU in patients with major organ involvement who might just omit FU for the fear of COVID-19 infection would be more pronounced. In a representative population of patients with significant lupus disease mostly requiring systemic glucocorticoid and immunosuppressive agents, we found that higher physician-assessed disease activity was associated with the preference of TM FU. This could be due to the fear of infection exposure during clinic visits in patients with more active disease, as we have previously found that choice of TM FU was associated with the perception that TM FU would reduce the risk of infection while routine care would increase that risk (10). In fact, a survey distributed to patients with SLE during the outbreak showed that their median fear of COVID-19 was 8 out of a maximum scale of 10 (32). Interestingly, in a study done before the COVID-19 outbreak, when offered as an option, video TM was also more likely to be used by rheumatoid arthritis patients with higher disease activity (33). Another possible explanation for the higher PGA in the TM group could be the perceived less stable disease when the patients were assessed virtually. It should also be noted that the small difference in PGA might not be clinically
meaningful. Other clinical factors such as lupus manifestations, objective activity, disease damage, pharmacotherapies, disability, and depression/anxiety symptoms did not seem to affect patients’ choice of mode of FU.

In this study, we also found that higher monthly family income favored TM use. Cavagna et al. reported the results of a survey on the propensity for adopting TM in 175 patients with connective tissue disease of whom 49 had SLE (11). It was found that a college degree and distance from the hospital were independent predictors for the acceptance of TM. It might seem conceivable that patients who are socio-economically more privileged would be keener to use TM (34). The issue needs to be addressed before universal integration between TM and standard care in order not to exacerbate health care disparities. On the other hand, we found no association in the distance from hospital with the preference of TM. This could be related to the fact that most of our patients were residing close to the hospital.

Another intriguing finding of the study is the association of fulltime employment status with standard in-person visit. Complete society lock-down or prohibition of social mobility was not in place in Hong Kong which meant patients with fulltime employment still had to go to work. As a result, the increased infection risk associated with attending the scheduled clinic FU might seem to be negligible.

There are several limitations in this study. First, the results should be interpreted in the context of the local outbreak status and mitigation measures implemented. Second, the study was conducted in a lupus nephritis clinic with mainly Asian patients having major organ involvement. The results might not be generalizable to the entire SLE population, which would include more patients with mild disease. Lastly, the suitability, mainly reflected by safety and efficacy, of TM FU in patients with SLE was not evaluated in the current study.

To conclude, when offered as an option in SLE patients, preference for TM FU was associated with non-fulltime employment, higher physician-determined disease activity, and better family income. With the availability of vaccines and gradual loosening of containment measures, the results could provide information on the factors to consider when we choose the mode of care delivery during and after the COVID-19 outbreak. The physician global assessment and socio-economic status, rather than other clinical factors such as treatments or comorbidities, appeared to be the important determinants of mode of follow-up in lupus patients.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Joint Chinese University of Hong Kong – New Territories East Cluster Clinical Research Ethics Committee, No. 2020-0254. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

HS, C-CS, and L-ST: study design. HS, EC, IC, S-LL, and TL: data collection and data analysis. HS and L-ST: drafting of manuscript. All authors critically revised the manuscript for important intellectual content.

ACKNOWLEDGMENTS

We would like to express our gratitude to all medical staff, research assistants, and participating patients. We would also like to thank the University of Central Lancashire and East Lancashire Hospitals NHS Trust for granting us permission to use the LupusQoL questionnaire.

REFERENCES

1. Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. (2013) 22:1286–94. doi: 10.1177/0961203313493032
2. Kuo CF, Chou II, Rees F, Grainge MJ, Lanyon P, Davenport G, et al. Temporal relationships between systemic lupus erythematosus and comorbidities. Rheumatology. (2019) 58:840–8. doi: 10.1093/rheumatology/key335
3. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. (2020) 368:m1091. doi: 10.1136/bmj.m1091
4. Zhu TY, Tam LS, Lee VW, Lee KK Li EK. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum. (2009) 61:1159–67. doi: 10.1002/art.24275
5. Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, Pastor-Asurza CA, Alfaro-Lozano JL, Cucho-Venegas JM, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis. (2015) 74:1019–23. doi: 10.1136/annrheumdis-2013-204620
6. Schulze-Koops H, Specker C, Ilking-Konert C, Holle J, Moosig F, Krueger K. Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. Ann Rheum Dis. (2020) 79:840–2. doi: 10.1136/annrheumdis-2020-217628
7. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1. Arthritis Rheumatol. (2020) 72:1241–51. doi: 10.1002/art.41301
8. Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. (2020) 79:851–8. doi: 10.1136/annrheumdis-2020-217877
9. Aries P, Welcker M, Callhoff J, Chehab G, Kruische M, Schneider M, et al. Statement of the German Society for Rheumatology (DGRh) on the use of video consultations in rheumatology. Z Rheumatol. (2020) 79:1078– 85. doi: 10.1007/s00393-020-00932-x
10. McDougall JA, Ferucci ED, Glover J, Fraenkel L. Telerheumatology: a systematic review. Arthritis Care Res (Hoboken). (2017) 69:1546–57. doi: 10.1002/acr.23153
11. Cavagna L, Zanframundo G, Codullo V, Pisu MG, Caporali R, Montecucco C. Telemedicine in rheumatology: a reliable approach beyond the pandemic. Rheumatology. (2021) 60:366–70. doi: 10.1093/rheumatology/kea554
12. So H, Szeto CC, Tam LS. Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak. *Ann Rheum Dis.* (2020) 80:e97. doi: 10.1136/annrheumdis-2021-218220

13. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis.* (2019) 78:1151–9. doi: 10.1136/annrheumdis-2020-218615

14. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. *Arthritis Rheum.* (2007) 57:972–9. doi: 10.1002/art.22881

15. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. *J Rheumatol.* (2003) 30:167–78.

16. Zigmond AS, Snith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* (1983) 67:361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x

17. Zhu TY, Tam L-S, Li EK. Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study. *Rheumatology.* (2011) 50:1293–301. doi: 10.1093/rheumatology/ker014

18. Zhu TY, Tam LS, Leung YY, Kwok LW, Wong KC Yu T, et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. *J Rheumatol.* (2010) 37:1214–20. doi: 10.3899/jrheum.090988

19. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol.* (2002) 29:288–91.

20. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis.* (2019) 78:736–45. doi: 10.1136/annrheumdis-2019-215089

21. Ekeland AG, Bowes A, Flottorp S. Effectiveness of telemedicine: a systematic review of reviews. *Int J Med Inform.* (2010) 79:736–71. doi: 10.1016/j.ijmedinf.2010.08.006

22. Fortney JC, Pyne JM, Mouden SB, Mittal D, Hudson TJ, Schroeder GW, et al. Practice-based vs. telemedicine-based collaborative care for depression in rural federally qualified health centers: a pragmatic randomized comparative effectiveness trial. *Am J Psychiatry.* (2013) 170:414–25. doi: 10.1176/appi.ajp.2012.12050966

23. Palacin-Marin F, Esteban-Moreno B, Olea N, Herrera-Viedma E, Arroyo-Morales M. Agreement between telerehabilitation and face-to-face clinical outcome assessments for low back pain in primary care. *Spine.* (2013) 38:947–52. doi: 10.1097/BRS.0b013e318281a36c

24. Armstrong AW, Chambers CJ, Maevakis E, Cheng MY, Dunnick CA, Chren M-M, et al. Effectiveness of online vs in-person care for adults with psoriasis: a randomized clinical trial. *JAMA Network Open.* (2018) 1:e183062. doi: 10.1001/jamanetworkopen.2018.3062

25. Nouhi M, Fayaz-Bakhsh A, Mohamadi E, Shafii M. Telemedicine and its potential impacts on reducing inequalities in access to health manpower. *Telemed J E Health.* (2012) 18:648–53. doi: 10.1089/tmj.2011.0242

26. Green LV, Savin S, Lu Y. Primary care physician shortages could be eliminated through use of teams, nonphysicians, and electronic communication. *Health Aff.* (2013) 32:11–9. doi: 10.1377/hlthaff.2012.1086

27. de Thurah A, Stengaard-Pedersen K, Axelsen M, Fredberg U, Schougaard LMV, Hjollund NHI, et al. Tele-health followup strategy for tight control of disease activity in rheumatoid arthritis: results of a randomized controlled trial. *Arthritis Care Res.* (2018) 70:353–60. doi: 10.1002acr.23280

28. Foti R, Amato G, Foti R, Visalli E. Management of patients with inflammatory rheumatic diseases: telemedicine and rheumatologists challenged in the era of COVID-19. *Frontiers in Public Health.* (2020) 8:558838. doi: 10.3389/fpubh.2020.558838

29. Maheswaranathan M, Chu P, Johannemann A, Criscione-Schreiber L, Clowse M, Levernitz DL. The Impact of the COVID-19 pandemic and telemedicine implementation on practice patterns and electronic health record utilization in an academic rheumatology practice. *J Clin Rheumatol.* (2021). doi: 10.1097/RHU.0000000000001751. [Epub ahead of print].

30. Lopez-Medina C, Escudero A, Collantes-Estevez E. COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases. *Ann Rheumatic Dis.* (2021) 80:e50. doi: 10.1136/annrheumdis-2020-218008

31. Chan A, Suarez A, Kitchen J, Bradlow A. Teleclinics in rheumatology introduced during the first lockdown phase of the COVID-19 pandemic of 2020. *Future Healthc J.* (2021) 8:e27–31. doi: 10.7861/fjh.2020-0093

32. Pedrosa T, Kupa LVK, Aikawa NE, Pasoto SG, Bonfá E, Silva CA. Lupus nephritis-related issues during COVID-19 pandemic quarantine. *Lupus.* (2020) 29:1978–80. doi: 10.1177/0961203320970998

33. Ferucci ED, Holck P, Day GM, Choromanski TL, Freeman SL. Factors associated with use of telemedicine for follow-up of rheumatoid arthritis. *Arthr Care Res.* (2020) 72:1404–9. doi: 10.1002acr.24049

34. Lattimore CM, Kane WJ, Fleming MA, Martin AN, Mehaffey JH, Smolkin ME, et al. Disparities in telemedicine utilization among surgical patients during COVID-19. *PloS ONE.* (2021) 16:e0258452. doi: 10.1371/journal.pone.0258452

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 So, Chow, Lau, Li, Szeto and Tam. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.